How hedge funds performed in a volatile November

Global hedge funds have generated nearly 15% year-to-date through end-November 2025, with long/short funds up 1.1% in November and systematic/quant strategies rising about 3.7% for their best monthly showing since March. Key drivers were concentrated bets in healthcare (sector +7% in November, ~30% YTD), U.S. exposure and crowded trades; TMT-focused funds fell 0.8% amid AI-bubble concerns even as stock pickers continued to accumulate U.S. TMT. Funds were net buyers of global equities for a third consecutive month—increasing North American exposure, rapidly selling European stocks, adding longs in Japan and covering Hong Kong shorts—and large multi-strategy players (Balyasny, Citadel, Schonfeld, Millennium) also posted gains in November.

Analysis

Market structure: Hedge funds and quant strategies are the short-term winners — long/short stock pickers +1.1% in November and quant funds +3.7% — driven by concentrated healthcare longs (XLV-like) and short exposure to stretched TMT names. That flow pattern tightens liquidity and raises bid for healthcare names (30% YTD to Nov), while imposing episodic selling pressure and higher implied volatility in high-multiple AI/tech names, compressing risk premia across concentrated equity pockets.

Risk assessment: Key tail risks are an AI regulatory or earnings shock that forces de-rating of high-multiple TMT names, a China liquidity event that reintroduces HK volatility, and a rapid deleveraging among hedge funds that could cascade into price discovery failure. Immediate (days) risk is a vol spike from quant de-grossing; short-term (weeks–months) risk is sector rotation if macro surprises; long-term (quarters) is valuation fatigue in healthcare absent earnings improvement.

Trade implications: Favor liquid healthcare exposure and systematic/quant sleeve while hedging AI concentration: long XLV and QAI-sized exposures, paired short exposure to overvalued TMT (QQQ) via options. Rotate out of European equities (VGK) into North American healthcare and Japan (EWJ) where flows are accelerating; use put spreads on concentrated tech names and sell covered calls on healthcare to monetize momentum.

Contrarian angle: Consensus underestimates re-risking into large-cap, cash-generative tech even as AI names suffer — stock pickers continue adding U.S. TMT for a reason. Healthcare’s +30% YTD looks vulnerable to a 10–20% mean reversion if macro slows or drug/price reforms surface; monitor short interest and ETF flows as early warning signals.

Key Decisions for Investors

• Establish a 3% long position in XLV (Health Care Select Sector SPDR) funded by trimming VGK (Vanguard FTSE Europe ETF) by 3%; horizon 3–6 months, take profits at +20% or trim if XLV underperforms QQQ by 10%, stop-loss at -10%.
• Initiate a regional pair: long EWJ (iShares MSCI Japan) 2% and reduce Europe exposure (additional 1% from VGK); hold 3–12 months to capture rotation and FX tailwinds, exit if USD/JPY moves >+4% or Japan PMI <48 on two prints.
• Hedge concentrated TMT/Ai risk with options: buy a 3-month QQQ put spread (buy ~8% OTM, sell ~15% OTM) sized to 0.5% portfolio risk premium; simultaneously sell 6-month covered calls on XLV at +15% OTM to harvest income.
• Allocate 2% to a liquid hedge-fund/quant ETF sleeve (e.g., QAI or similar multi-strategy ETF) to capture systematic alpha; rebalance quarterly and cut exposure if it lags S&P by >5% over any 60-day window.